Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

El efecto de la acupresión sobre el dolor, las náuseas y los vómitos y el bienestar mental en pacientes oncológicos

29 de septiembre de 2026 actualizado por: Esra Cavusoglu, Mersin University

El efecto de la acupresión autoadministrada y la acupresión aplicada por el terapeuta sobre el dolor, las náuseas y los vómitos y el bienestar mental en pacientes oncológicos: un estudio controlado aleatorio de tres brazos

The goal of this clinical trial is to compare the effect of self acupressure and acupressure applied by therapists on pain, nausea-vomiting, and mental well-being in oncology patients.

For this purpose, 96 individuals with stage 1-stage 3 cancer will be included in the study.

The main questions it aims to answer are:

• Is acupressure effective on pain, nausea-vomiting and mental well-being in oncology patients? Is there a difference in the effectiveness of self-acupressure and acupressure applied by therapist on pain, nausea-vomiting and mental well-being? The participants will be included in the study as three groups, namely the self-acupressure group, the acupressure group applied by the therapist, and the control group.

Self-acupressure participants will self-administer acupressure. In the acupressure group, which will be applied by the therapist, acupressure will be applied to the participants by researchers who have acupressure certificate.

In the control group, acupressure etc. No additional application will be made. Visual analog scale, nausea-vomiting and retching index, and mental well-being scales will be applied to all groups at the beginning of the study and three days after the study.

Descripción general del estudio

Descripción detallada

Large Intestine Meridian 4th point (Hegu/LI4), Pericardium Meridian/Neiguan (P6) point and Yintang (EX-HN 3) point will be used for acupressure application in the research.

Tipo de estudio

Intervencionista

Inscripción (Actual)

96

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Yenişehir
      • Mersin, Yenişehir, Turquía (Türkiye)
        • Mersin University Faculty of Nursing

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • ≥18 years
  • Cancer patients without distant metastases in stage-1, stage-2 and stage-3 who have received at least one course of chemotherapy
  • Pain degree 4 and above (will be evaluated with a visual analog scale)
  • Nausea-vomiting degree of 4 and above (will be evaluated with a visual analog scale)
  • Receiving standard antiemetic and standard analgesic treatment (All patients included in the study should receive similar treatment.)
  • No previous acupressure experience
  • Absence of any wound or lesion in the area where acupressure will be applied.
  • Not using a different complementary approach during the collection of research data
  • Those who signed the Informed Consent Form/Written Consent Form
  • Patients without any psychiatric diagnosis will be included in the study.

Exclusion Criteria:

  • < 18 years old
  • Those who have not received chemotherapy before
  • Pain grade below 4 (will be evaluated with a visual analog scale)
  • Nausea-vomiting degree below 4 (will be evaluated with a visual analog scale)
  • Receiving different antiemetic and analgesic treatments
  • Previous acupressure experience
  • Any wound or lesion in the area where acupressure will be applied
  • Using a complementary approach other than acupressure at the time research data was collected
  • Those who did not sign the Informed Consent Form/Written Consent Form
  • Patients with any psychiatric diagnosis will not be included in the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Self acupressure group

The first acupressure application will be administered and taught individually by the researcher to the oncology patients in the self-administered group. Afterwards, each patient who learns the application will be asked to apply acupressure on his own for three days. In the self-acupressure group, a questionnaire form consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied first (pre-test) before the acupressure application is taught to the group by the researchers. Afterwards, patients will apply acupressure on their own for three days, and at the end of this period (post-test), a questionnaire consisting of personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied. Acupressure will be applied the large intestine meridian 4th Point (LI4), the pericardium meridian Neiguan (P6) and Yintang (EX-HN3).

In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants

Otro: Acupressure by therapist

In this group, acupressure will be administered to stage I, stage II, and stage III cancer patients receiving at least one course of chemotherapy for a total of three days by researchers with acupressure certification. Before the application (pre-test) by the therapist, a questionnaire consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied to the patients in the group in question. At the end of the three-day acupressure application (post-test) applied to the patients included in the study by the therapist, a questionnaire consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied. In the acupressure group applied by the therapist, a total of three points will be applied to the upper extremity: the 4th point of the large intestine meridian (LI4), the Pericardium Meridian/Neiguan (P6), Yintang (EX-HN3) point.

In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.

Otro: Control group

The control group will receive the routine treatment applied in the hospital, and acupressure will not be applied to this group.

No intervention will be made in the control group.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pain intensity will be evaluated with a visual analog scale.
Periodo de tiempo: Change from baseline pain level at 3 days

The patient evaluates their own pain using a scale ranging from 1 to 10, with 1 = very mild discomfort and 10 = the most severe pain the patient can imagine. Ranges for pain intensity; <3 mild pain, 3-6 moderate pain, >6 severe pain.

Change from baseline pain level at 3 days
Nausea-vomiting severity will be evaluated with the Rhodes Nausea-Vomiting and Retching Index.
Periodo de tiempo: Change from baseline nausea-vomiting level at 3 days

Each response is scored as 0 = least distress, 4 = most distress. The patient's experience of nausea and vomiting in each of the 8 items is summed up. The highest possible value is 32, indicating the most severe symptom occurrence score.

Change from baseline nausea-vomiting level at 3 days
Mental well-being will be evaluated using the Warwick-Edinburgh Mental Well-Being Scale.
Periodo de tiempo: Change from baseline mental well-being level at 3 days

The scale is in the 5-point Likert type and a minimum of 14 and a maximum of 70 points are obtained from the scale. Scoring of the scale is (1 = strongly disagree, 2 = disagree, 3 = somewhat agree, 4 = agree, 5 = completely agree).

Change from baseline mental well-being level at 3 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Esra Çavuşoğlu, Doctorate, Mersin University
  • Investigador principal: Hilal Altundal Duru, Doctorate, Çankırı Karatekin University
  • Investigador principal: Kadir Eser, Mersin University
  • Investigador principal: Emel Sezer, Mersin University
  • Investigador principal: Vehbi Erçolak, Mersin University
  • Investigador principal: Ümmügülsüm Kılıç, Mersin University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de junio de 2023

Finalización primaria (Actual)

5 de junio de 2023

Finalización del estudio (Actual)

30 de septiembre de 2023

Fechas de registro del estudio

Enviado por primera vez

22 de mayo de 2023

Primero enviado que cumplió con los criterios de control de calidad

1 de junio de 2023

Publicado por primera vez (Actual)

12 de junio de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir